Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

NCT: NCT06847542 · RECRUITING

NCT IDNCT06847542
StatusRECRUITING
Start Date2025-11-27
Completion2028-11-15

Brief Summary

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

Frequently Asked Questions

What is A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD?

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD is a clinical trial registered under NCT06847542. Current status: RECRUITING.

What is the status of NCT06847542?

The current status of NCT06847542 (A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD) is: RECRUITING.

When did A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD start?

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD started on 2025-11-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑